长春瑞滨联合卡铂治疗老年晚期非小细胞肺癌  

Clinical observation of Navelbine and Carboplatin in treating elder advanced non-small-cell lung cancer

作　　者：庞红霞[1] 

机构地区：[1]泉州市第一医院肿瘤科

出　　处：《临床肿瘤学杂志》2004年第6期628-629,共2页Chinese Clinical Oncology

摘　　要：目的 :观察长春瑞滨 (诺维本 ,NVB)联合卡铂化疗方案治疗老年晚期非小细胞肺癌患者的临床疗效及不良反应。方法 :对住院治疗的 2 5例老年晚期非小细胞肺癌患者采用NVB联合卡铂化疗方案 ,NVB 2 5mg/m2 第 1、8天 ,卡铂 35 0mg/m2 第 1天。每 4周重复 ,至少治疗两周期 ,按标准评价疗效和毒副反应。结果 :可评价患者 2 5例 ,有效率为 4 8% ,中位生存期 7个月 ,1年生存率为 32 %。主要毒性反应为骨髓抑制、消化道反应及静脉炎 ,多数为Ⅰ～Ⅲ度反应。结论 :NVB联合卡铂方案治疗老年晚期非小细胞肺癌临床疗效较好 。Objective:To observe the clinical efficacy and side reaction of navelbine(NVB) and carboplatin(CBP) regimen in elder patients with advanced non-small-cell lung cancer (NSCLC).Methods:Twenty-five elder patients with unresectable NSCLC were enrolled for this study.Navelbine were administered 25 mg/m 2 on day 1,8 and carboplatin 350 mg/m 2 on day 1 intravenously every 4 weeks and with at least 2 cycles.Results:In the 25 evaluable cases the response rate was 48%,Median survival time was 7 months and 1 year survival rate was 32%.The main toxicity was myelosuppression,gastrointestinal tract reaction and phlebitis.The most were grade 1 or 3.Conclusion:The schedule of navelbine and carboplatin on elder advanced NSCLC has good clinical efficacy and tolerability.

关 键 词：治疗 卡铂 晚期非小细胞肺癌 老年 NVB 联合 长春瑞滨 患者 化疗方案 毒性反应 

分 类 号：R734[医药卫生—肿瘤] R735.7[医药卫生—临床医学]